A functional prognostic model predicts progression-free survival in patients with relapsed chronic lymphocytic leukemia treated with ibrutinib + venetoclax.

Authors

Johanne U Hermansen, Weikaixin Kong, Andrea M Brodersen, Yanping Yin, Aleksandra Urban, Idun D Rein, Liye He, Rudi Agius, Rebecca S Teglgaard, Juho Rousu, Christian Brieghel, Sabina Kersting, Mark-David Levin, Hoa T T Tran, Mattias Mattsson, Juha Ranti, Gerrit-Jan Veldhuis, Caspar da Cunha-Bang, Rogier Mous, Julie Dubois, Arnon P Kater, Jorrit M Enserink, Carsten U Niemann, Tero Aittokallio, Sigrid S Skånland

Published in

HemaSphere. Volume 10. Issue 9. Pages e70467. Epub Sep 17, 2026.

Abstract

Targeted therapies have improved outcomes for patients with chronic lymphocytic leukemia (CLL); yet, not all achieve durable responses. Existing prognostic models, developed for chemoimmunotherapy, have limited predictive value for newer targeted combinations. Here, we used data from a randomized phase II clinical trial to identify predictors of progression-free survival (PFS) in response to Bruton tyrosine kinase (BTK) + B-cell lymphoma 2 (Bcl-2) inhibitor combination therapy. We studied the functional, genetic, and clinical characteristics of patients with relapsed/refractory (R/R) CLL treated with ibrutinib + venetoclax in the VISION/HO141 clinical trial (NCT03226301). Ex vivo drug sensitivity testing, (phospho)protein profiling, and immunophenotyping were performed on baseline peripheral blood mononuclear cells from 177 patients. Ex vivo drug sensitivity correlated with clinical responses to single-agent therapies. (Phospho)protein patterns reflected intracellular pathway activity and predicted ex vivo drug sensitivity. Using stringent feature selection and regularized ridge regression to prevent overfitting, we integrated functional, genetic, and clinical data sets and identified six features-sensitivity to VEGFR-2-, JAK1/2 + Bcl-2-, and BTK + PI3K-inhibitors; phosphorylation ratios of Bcl-2:BTK and p90RSK:PLCγ2; and frequency of CD8⁺ T cells-that together outperformed the International Prognostic Index for CLL (CLL-IPI) and other clinical scores in predicting PFS. These findings demonstrate that a prognostic model based on the functional features of CLL cell signaling and interaction with the microenvironment has the potential to improve upon conventional prognostic scores, warranting further clinical validation also in the frontline setting.

PMID:
42757031
Bibliographic data and abstract were imported from PubMed on 18 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.